Cobicistat
- Generic Name
- Cobicistat
- Brand Names
- Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Tybost
- Drug Type
- Small Molecule
- Chemical Formula
- C40H53N7O5S2
- CAS Number
- 1004316-88-4
- Unique Ingredient Identifier
- LW2E03M5PG
- Background
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that ar...
- Indication
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due...
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 7
- Registration Number
- NCT02503462
- Locations
- 🇨🇭
Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland
Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination
- Conditions
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 72
- Registration Number
- NCT02475135
Taste Properties of Atazanavir and Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT02307656
- Locations
- 🇺🇸
Senopsys Llc, Woburn, Massachusetts, United States
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 32
- Registration Number
- NCT02277600
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 130
- Registration Number
- NCT02016924
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Thailand
🇹🇭Srinagarind Hospital, Khon Kaen, Thailand
🇹🇭Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand
The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 40
- Registration Number
- NCT01896622
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 64
- Registration Number
- NCT01837719
- Locations
- 🇺🇸
Ppd Development, Inc., Austin, Texas, United States
A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 133
- Registration Number
- NCT01619527
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.